Management of Hyperkalemia in Patients with Chronic Kidney Disease Using Renin Angiotensin Aldosterone System

Michelle A Fravel1, Calvin J Meaney2, Lama Noureddine3

  • 1University of Iowa College of Pharmacy, 167 CPB, 180 S. Grand Ave, Iowa City, IA, 52242, USA. michelle-fravel@uiowa.edu.

Current Hypertension Reports
|September 25, 2023
PubMed

Insights

Managing hyperkalemia in chronic kidney disease (CKD) patients on renin-angiotensin-aldosterone system (RAAS) inhibitors requires prioritizing strategies that maintain RAAS inhibitor therapy. This approach preserves kidney and cardiovascular protection, crucial for patient outcomes.

Area of Science:

  • Nephrology
  • Cardiology
  • Internal Medicine

Background:

  • Renin-angiotensin-aldosterone system (RAAS) inhibitors are vital for cardiovascular disease and kidney function in chronic kidney disease (CKD) patients.
  • Hyperkalemia, a risk factor for arrhythmias and mortality, is a common complication of RAAS inhibitor use in CKD.
  • Discontinuing RAAS inhibitors due to hyperkalemia can negate their protective benefits.

Purpose of the Study:

  • To outline critical management principles for hyperkalemia in CKD patients on RAAS inhibitors.
  • To emphasize strategies that allow for the continuation of RAAS inhibitor therapy.
  • To balance the risks of hyperkalemia with the benefits of RAAS inhibition.

Main Methods:

  • Prioritize hyperkalemia mitigation strategies that do not interfere with RAAS inhibitor therapy.
  • Discontinue non-RAAS inhibitor medications causing hyperkalemia.
  • Correct metabolic acidosis and maximize potassium-lowering medications like diuretics and SGLT-2 inhibitors.
  • Consider potassium exchange resins for sustained RAAS inhibitor use.
  • Employ concurrent strategies for effective hyperkalemia management.

Main Results:

  • Concurrent application of multiple strategies is key to mitigating hyperkalemia and maintaining RAAS inhibitor therapy.
  • Persistence of RAAS inhibitor use slows kidney function decline and prevents adverse cardiovascular events.
  • A deliberate approach to reduce serum potassium allows for continuation of maximally dosed RAAS inhibitors.
  • Patient education and engagement are vital for successful potassium management.

Conclusions:

  • Effective hyperkalemia management in CKD patients on RAAS inhibitors is essential for preserving renal and cardiovascular protection.
  • A multi-faceted approach, including lifestyle and medication adjustments, enables sustained RAAS inhibitor therapy.
  • Maintaining RAAS inhibitor therapy is crucial for long-term patient outcomes in CKD.
Abstract

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
667
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
28
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
12
Acute Kidney Injury VI: Nursing Management01:22

Acute Kidney Injury VI: Nursing Management

Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
19
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
612